Abstract
The development of anti-drug antibodies (ADAs) is a common cause for treatment failure and hypersensitivity reactions for many biologics. The focus of this review is the development of ImmTOR, a platform technology designed to prevent the formation of ADAs that can be applied broadly across a wide variety of biologics by inducing immunological tolerance with ImmTOR nanoparticles encapsulating rapamycin. The induction of tolerance is antigen-specific and dependent on the incorporation of rapamycin in nanoparticles and the presence of the antigen at the time of administration of ImmTOR. Evidence for the induction of specific immune tolerance vs. general immune suppression is supported by the findings that: (1) ImmTOR induces regulatory T cells specific to the co-administered antigen; (2) tolerance can be transferred by adoptive transfer of splenocytes from treated animals to naïve recipients; (3) the tolerance is durable to subsequent challenge with antigen alone; and (4) animals tolerized to a specific antigen are capable of responding to an unrelated antigen. ImmTOR nanoparticles can be added to new or existing biologics without the need to modify or reformulate the biologic drug. The ability of ImmTOR to mitigate the formation of ADAs has been demonstrated for coagulation factor VIII in a mouse model of hemophilia A, an anti-TNFα monoclonal antibody in a mouse model of inflammatory arthritis, pegylated uricase in hyperuricemic mice and in non-human primates, acid alpha-glucosidase in a mouse model of Pompe disease, recombinant immunotoxin in a mouse model of mesothelioma, and adeno-associated vectors in a model of repeat dosing of gene therapy vectors in mice and in non-human primates. Human proof-of concept for the mitigation of ADAs has been demonstrated with SEL-212, a combination product consisting of ImmTOR + pegadricase, a highly immunogenic enzyme therapy for the treatment of gout. ImmTOR represents a promising approach to preventing the formation of ADAs to a broad range of biologic drugs.
Highlights
The rise of biological therapies, first from natural sources and more recently from recombinant DNA technology, has heralded a revolution in medicine [1, 2]
Protein engineering has aided in reducing the risk of immunogenicity, but even biologics derived from human sequences, such as growth factors [8] and therapeutic monoclonal antibodies [9] can elicit anti-drug antibodies (ADAs) resulting in late stage clinical trial failure [10, 11]
We initially demonstrated that nanoparticles that coencapsulated both rapamycin and antigen were effective at inducing durable antigen-specific immunological tolerance in vivo, including against coagulation factor VIII in a mouse model of hemophilia A (Figure 2) [34]
Summary
The rise of biological therapies, first from natural sources and more recently from recombinant DNA technology, has heralded a revolution in medicine [1, 2]. Recipient SJL mice treated with ImmTOR nanoparticles containing rapamycin and PLP peptide, but not with ImmTOR particles containing rapamycin without antigen, were protected from the development of experimental autoimmune encephalomyelitis following subsequent transfer of activated PLP-specific encephalitogenic T cells [46] These results provide further evidence for an induction of an antigen-specific regulatory cell population capable of inhibiting activated effector T cells. Five weekly co-administrations of ImmTOR particles containing rapamycin with therapeutic doses of free FVIII induced durable mitigation of ADAs that was maintained for at least 5 months despite repeated challenges of FVIII alone but did comprise the immune response to other antigens. Recombinant pegylated uricase has been developed as a promising therapy for the treatment of chronic
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
